معرفی
Dr. Jacobi Hines serves as an Assistant Professor in the Department of Medicine (Hematology and Oncology) at Northwestern University's Feinberg School of Medicine. He is an active clinician-researcher at the Robert H. Lurie Comprehensive Cancer Center, specializing in lung cancer therapeutics.
Research Focus: His work centers on targeted therapies and immunotherapies for non-small cell lung cancer (NSCLC), with particular emphasis on RET, EGFR, and HER2 mutations. He investigates resistance mechanisms and novel combination strategies to improve patient outcomes.
Recent Publications: In 2024, Dr. Hines contributed to studies on surrogate endpoints for neoadjuvant immunotherapy in NSCLC and case reports on RET fusion-positive NSCLC with acquired resistance. His research bridges clinical trial design and molecular oncology.
Clinical Trials Leadership: He currently leads two major trials: a Phase I/II study of EP0031 for RET-altered cancers (NCT05443126) and a first-in-human trial of BH-30643 for EGFR/HER2-mutant NSCLC (NCT06706076), both recruiting at Northwestern Medicine.
